A Systematic Review of Accelerated Intermittent Theta Burst Stimulation (iTBS) Versus Daily Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Depression: Is Shorter Really Better? Authors: Ayushi Saxena, Bilal Khan, Rupanshu Rupanshu, Russaal S Mann, Isha Chopra, Abdullah Kilic, Pousette F Hamid Published: 2026 ABSTRACT Treatment-resistant depression (TRD) presents a major clinical challenge, with a significant proportion of patients failing to respond to standard therapies. Among the neuromodulation options available, repetitive transcranial magnetic stimulation (rTMS) has been widely studied and approved, though it requires daily sessions over several weeks. Intermittent theta burst stimulation (iTBS), particularly in accelerated formats, offers a faster, time-efficient alternative that may maintain or enhance clinical outcomes. This systematic review synthesizes evidence from 25 studies comparing accelerated iTBS protocols to standard daily rTMS in adult TRD populations, with attention to efficacy, cognitive impact, tolerability, and logistical feasibility. Our findings suggest that accelerated iTBS is non-inferior to rTMS in terms of antidepressant outcomes, with comparable cognitive safety and fewer barriers to access. By reducing treatment duration without compromising results, accelerated iTBS represents a compelling option in the evolving landscape of depression management and may offer particular advantages for patients with limited access to extended care. Introduction and background Major depressive disorder (MDD) remains one of the most disabling mental illnesses worldwide, affecting more than 300 million people and contributing significantly to the global burden of disease [1]. Although pharmacological and psychotherapeutic treatments are first-line for MDD, a substantial proportion of patients fail to achieve a satisfactory response. This subset, defined as treatment-resistant depression (TRD), accounts for up to 30% of patients and presents significant clinical, functional, and economic challenges [2]. TRD is most commonly operationalized as the failure to achieve an adequate clinical response despite two or more trials of antidepressant medication, each administered at an adequate dose and for an adequate duration (typically at least 4-6 weeks) [2]. TRD is associated with increased suicide risk, poor quality of life, and higher healthcare utilization. Conventional treatment approaches such as augmentation, medication switching, or electroconvulsive therapy (ECT) often involve trade-offs between efficacy, tolerability, and accessibility. In this context, neuromodulation techniques have gained prominence, particularly repetitive transcranial magnetic stimulation (rTMS), which was approved by the U.S. FDA in 2008 as a treatment for TRD [3]. rTMS typically involves high-frequency magnetic stimulation of the left dorsolateral prefrontal cortex (DLPFC), administered daily over 4-6 weeks. Despite demonstrated efficacy, this regimen requires significant time and resource commitment, which can pose barriers to widespread implementation, particularly in underserved or rural settings, or among patients balancing occupational or caregiving responsibilities [4,5]. To address these limitations, theta burst stimulation (TBS) was developed as a more time-efficient variation. TBS delivers bursts of high-frequency pulses in a pattern mimicking endogenous hippocampal theta rhythms known to promote neuroplasticity. Among its protocols, intermittent TBS (iTBS) delivers treatment in just three minutes per session, which is a significant reduction compared to the 37.5 minutes required for standard rTMS while maintaining comparable clinical efficacy [6]. The landmark THREE-D trial established the non-inferiority of iTBS to rTMS in TRD [7], prompting growing interest in further condensing treatment through accelerated iTBS (aiTBS). These protocols administer multiple iTBS sessions per day, often completing a full course within five to seven days [8]. This acceleration may reduce dropout rates, enhance treatment adherence, and offer earlier relief of depressive symptoms. However, despite growing use, key questions remain about how aiTBS compares to daily rTMS in terms of efficacy, cognitive safety, tolerability, and clinical practicality. The aim of this systematic review is to synthesize current evidence comparing accelerated iTBS with standard daily rTMS in adults with TRD, focusing on clinical outcomes, cognitive effects, protocol efficiency, and implementation feasibility to help inform evidence-based clinical decision-making. Figure 1 depicts the symptoms of MDD. Symptoms of major depressive disorder Image credits: Ayushi Saxena Created with BioRender.com [9] Review Methods Search Strategy and Databases We conducted a systematic review in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Databases searched included PubMed, ScienceDirect, JAMA Psychiatry, Psychiatry Online, American Journal of Psychiatry, and PMC, covering literature published up to May 2025. Search terms included “intermittent theta burst stimulation,” “accelerated iTBS,” “repetitive transcranial magnetic stimulation,” “rTMS,” “treatment-resistant depression,” and “neuromodulation.” Boolean operators and MeSH terms were applied when appropriate. PubMed's MeSH database is as follows: "ITBS"[All Fields] AND ("transcranial magnetic stimulation"[MeSH Terms] OR ("transcranial"[All Fields] AND "magnetic"[All Fields] AND "stimulation"[All Fields]) OR "transcranial magnetic stimulation"[All Fields] OR "rtms"[All Fields]) AND ("depressive disorder"[MeSH Terms] OR "depression"[MeSH Terms]). Study Selection Process Articles were imported into EndNote (Clarivate, London, United Kingdom), and duplicates were removed. Screening based on titles and abstracts was followed by full-text review. Final study selection was made based on eligibility and relevance. A total of 25 studies were selected after applying inclusion/exclusion criteria. Quality Assessment Study quality was evaluated using appropriate tools based on design: the Newcastle-Ottawa Scale (NOS) for observational studies, AMSTAR for systematic reviews, and SANRA for narrative reviews. The ROBIS tool was used to assess risk of bias in systematic reviews. Only studies meeting acceptable quality thresholds were included. Table 1 presents the identified numbers of papers for each database, and the full PRISMA flowchart [10] is illustrated in Figure 2. Table 1The databases used and the identified numbers of papers for each databaseAbbreviations: iTBS = Intermittent Theta Burst Stimulation; rTMS = Repetitive Transcranial Magnetic Stimulation; TBS = Theta Burst Stimulation; TMS = Transcranial Magnetic Stimulation; MeSH = Medical Subject Headings; PMC = PubMed CentralSearch StrategyDatabase UsedNumber of Papers Identified((ITBS) AND (RTMS)) AND (DEPRESSION)PubMed251((ITBS) AND (RTMS)) AND (DEPRESSION [MeSH Terms])PubMed [MeSH]126iTBS vs daily rTMS for depressionScienceDirect328TBS AND TMSAmerican Journal Of Psychiatry28TBS AND TMSPsychiatry Online78TBS TMSJAMA Psychiatry92Theta Burst Stimulation"[MeSH] OR "Intermittent Theta Burst Stimulation" OR iTBS OR "accelerated iTBSPMC391 The databases used and the identified numbers of papers for each database Abbreviations: iTBS = Intermittent Theta Burst Stimulation; rTMS = Repetitive Transcranial Magnetic Stimulation; TBS = Theta Burst Stimulation; TMS = Transcranial Magnetic Stimulation; MeSH = Medical Subject Headings; PMC = PubMed Central PRISMA flowchart Abbreviations: PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; ECT = Electroconvulsive Therapy; tDCS = Transcranial Direct Current Stimulation; iTBS = Intermittent Theta Burst Stimulation; TBS = Theta Burst Stimulation; rTMS = Repetitive Transcranial Magnetic Stimulation Source: [12] Inclusion and Exclusion Criteria Table 2 summarizes the inclusion and exclusion criteria used in the review. Table 2Exclusion and inclusion criteriaAbbreviations: iTBS = Intermittent Theta Burst Stimulation; ECT = Electroconvulsive Therapy; tDCS = Transcranial Direct Current Stimulation; DBS = Deep Brain StimulationInclusion Criteria Exclusion CriteriaStudies published between 2009 and 2025Studies published before 2009Formally published, peer-reviewed academic literature indexed in recognized scientific databases.Gray literaturePublished in EnglishPublished in languages other than EnglishHuman studiesAnimal model studiesInterventions involving intermittent theta burst stimulation (iTBS), including accelerated protocolsOther neuromodulation interventions (e.g., ECT, tDCS, DBS)Reports clinical outcomes (e.g., response, remission, dropout, safety, or cognitive effects)No extractable clinical outcome data reported Exclusion and inclusion criteria Abbreviations: iTBS = Intermittent Theta Burst Stimulation; ECT = Electroconvulsive Therapy; tDCS = Transcranial Direct Current Stimulation; DBS = Deep Brain Stimulation Study Selection A total of 1294 records were retrieved through database searches and imported into EndNote (Clarivate, London, United Kingdom). After removal of duplicates, all remaining titles and abstracts were screened for relevance. Of these, 138 full-text articles were evaluated against predefined inclusion and exclusion criteria. After this process, 25 studies that met all eligibility parameters were finalized for inclusion in this systematic review. Quality Assessment Each study included in the review was evaluated using quality-assessment tools appropriate for its methodology. Observational studies were examined with the NOS, which considers how participants were selected, how well groups were matched, and how outcomes were assessed. Systematic reviews were judged using the AMSTAR checklist, while narrative reviews were assessed with the SANRA criteria. The ROBIS tool was also applied to evaluate risks of bias across domains such as study identification, relevance, and synthesis. To ensure accurate interpretation of the evidence, earlier reviews addressing neuromodulation methodology and cognitive safety were consulted as additional context [11,12]. Only studies that met basic methodological standards were retained, and the results of these quality assessments are summarized in Table 3 according to study design and the tool used. Table 3Quality assessment of the included studiesNotes: Quality ratings were assigned using design-appropriate appraisal frameworks. Randomized controlled trials were evaluated using the CONSORT criteria, observational registry studies were evaluated using the Newcastle–Ottawa Scale, and open-label accelerated protocols (e.g., Duprat et al.) were assessed using narrative appraisal methods, as standardized tools are not applicable to uncontrolled designs. Population descriptors reflect the primary participant group in each study.The Newcastle–Ottawa Scale is a quality appraisal tool for observational studies. Narrative appraisal is a quality assessment method for non-randomized or open-label studies.Abbreviations: TRD = Treatment-Resistant Depression; RCT = Randomized Controlled Trial; Deep TMS = Deep Transcranial Magnetic Stimulation; CONSORT = Consolidated Standards of Reporting TrialsStudyDesignSample SizePopulationTool UsedQuality RatingFitzgerald et al. [4]RCT90TRD, adultsCONSORTHighBlumberger et al. [6]RCT414TRD, adultsCONSORTHighCash et al. [7]RCT76TRD, adultsCONSORTHighCole et al. [8]RCT29TRD, adultsCONSORTHighKishi et al. [19]Pilot RCT30TRD, adultsCONSORTModerateBlumberger et al. (Deep TMS) [20]RCT (Deep TMS)199Late-Life TRDCONSORTHighIshtiak-Ahmed et al. [26]Registry Cohort1,230Real-world TRDNewcastle-OttawaModerateDuprat et al. [27] Open-label accelerated protocol50TRD, adultsNarrative appraisalModerate Quality assessment of the included studies Notes: Quality ratings were assigned using design-appropriate appraisal frameworks. Randomized controlled trials were evaluated using the CONSORT criteria, observational registry studies were evaluated using the Newcastle–Ottawa Scale, and open-label accelerated protocols (e.g., Duprat et al.) were assessed using narrative appraisal methods, as standardized tools are not applicable to uncontrolled designs. Population descriptors reflect the primary participant group in each study. The Newcastle–Ottawa Scale is a quality appraisal tool for observational studies. Narrative appraisal is a quality assessment method for non-randomized or open-label studies. Abbreviations: TRD = Treatment-Resistant Depression; RCT = Randomized Controlled Trial; Deep TMS = Deep Transcranial Magnetic Stimulation; CONSORT = Consolidated Standards of Reporting Trials Although 25 studies met the initial eligibility criteria, several could not be included in the tabular synthesis due to methodological differences or insufficient outcome reporting. Narrative and mechanistic papers [13-17] contributed important context regarding the neurobiological basis of iTBS, including its alignment with endogenous theta rhythms and its role in synaptic plasticity, but did not provide extractable clinical outcomes. Real-world and registry-type analyses [17-20] offered insight into treatment utilization and patient adherence, although these studies lacked standardized measures of response or remission. A separate group of investigations focused specifically on cognitive outcomes following neuromodulation, with recent systematic reviews demonstrating that non-invasive brain stimulation is cognitively safe and may confer modest improvements in executive functioning and processing speed [21-23]. However, these studies did not report the clinical efficacy endpoints required for inclusion in quantitative tables. Finally, several smaller pilot or feasibility studies [24-26] explored alternative stimulation parameters or targeted subpopulations, but their limited sample sizes and non-comparative designs necessitated narrative rather than tabular synthesis. For these reasons, only randomized controlled trials and observational studies that reported clear, extractable clinical outcomes were included in Tables 3, 4. All other studies were retained in the review and integrated narratively within the Results and Discussion sections to ensure a comprehensive interpretation of the available evidence. Table 4 Clinical Outcomes of Accelerated iTBS vs. Daily rTMSNotes: Response and remission rates reflect outcomes measured using standardized depression rating scales (typically HAM-D or MADRS). "Duration" refers to the length of the active treatment protocol rather than follow-up. Dropout rates indicate discontinuation prior to completing the assigned stimulation schedule. Adverse events represent those reported within each study and were generally mild and transient across protocols. Accelerated protocols (aiTBS and SAINT) involve multiple iTBS sessions delivered per day over a condensed timeframe (4-5 days). Open-label accelerated protocols (e.g., Duprat et al.) report outcomes without a control group but align conceptually with other short-course aiTBS paradigms.Abbreviations: iTBS = Intermittent Theta Burst Stimulation; aiTBS = Accelerated Intermittent Theta Burst Stimulation; rTMS = Repetitive Transcranial Magnetic Stimulation; Saint = Stanford Accelerated Intelligent Neuromodulation Therapy; tDCS = Transcranial Direct Current Stimulation; Deep TMS = Deep Transcranial Magnetic Stimulation; H-coil = Coil Configuration Used in Deep TMS; TRD = Treatment-Resistant Depression; AE = Adverse EventStudyTreatment ProtocolDurationResponse RateRemission RateDropout RateAdverse EventsFitzgerald et al. [4]iTBS (2× daily, 7 days)1 week42%20%5%Insomnia, headacheBlumberger et al. [6]iTBS (600 pulses/session, 1× daily) vs. rTMS4–6 weeks49% (iTBS), 47% (rTMS)25% vs. 24%<10%Headache, scalp discomfortCash et al. [7]iTBS (5× daily, 5 days) vs. rTMS5 days vs. 6 weeks45% vs. 43%22% vs. 20%<10%Fatigue, mild discomfortCole et al. [8]SAINT protocol (10 sessions/day × 5 days)5 days~53%~28%8%Mild headacheKishi et al. [19]iTBS or tDCS (multiple sessions)4–5 days~35%~15%6%Transient headacheBlumberger et al. (Deep TMS) [20]Deep TMS (H-coil)4 weeks~35–40%~15–20%~10%Headache, discomfortIshtiak-Ahmed et al. [26]Registry-based accelerated iTBS vs. rTMSVariable22% vs. 25%11% vs. 12%9%Not systematically reportedDuprat et al. [27]Accelerated iTBS (20 sessions over 4 days)4 days18% (↑ to ~38% at follow-up)7–10%0–5%Mild headache, scalp discomfort Clinical Outcomes of Accelerated iTBS vs. Daily rTMS Notes: Response and remission rates reflect outcomes measured using standardized depression rating scales (typically HAM-D or MADRS). "Duration" refers to the length of the active treatment protocol rather than follow-up. Dropout rates indicate discontinuation prior to completing the assigned stimulation schedule. Adverse events represent those reported within each study and were generally mild and transient across protocols. Accelerated protocols (aiTBS and SAINT) involve multiple iTBS sessions delivered per day over a condensed timeframe (4-5 days). Open-label accelerated protocols (e.g., Duprat et al.) report outcomes without a control group but align conceptually with other short-course aiTBS paradigms. Abbreviations: iTBS = Intermittent Theta Burst Stimulation; aiTBS = Accelerated Intermittent Theta Burst Stimulation; rTMS = Repetitive Transcranial Magnetic Stimulation; Saint = Stanford Accelerated Intelligent Neuromodulation Therapy; tDCS = Transcranial Direct Current Stimulation; Deep TMS = Deep Transcranial Magnetic Stimulation; H-coil = Coil Configuration Used in Deep TMS; TRD = Treatment-Resistant Depression; AE = Adverse Event Results S tudy Identification and Selection A comprehensive database search yielded a total of 1,294 records. After eliminating 269 duplicates and excluding 887 articles based on title and abstract screening, 138 full-text articles were retrieved and assessed for eligibility. Of these, 113 were excluded for reasons such as non-comparative design, irrelevant patient population, or insufficient outcome data. A total of 25 studies met all inclusion criteria and were included in this systematic review. The detailed selection process is illustrated in the PRISMA 2020 flowchart (Figure 2). Study Characteristics The final 25 studies included randomized controlled trials, observational cohorts, pilot studies, cognitive testing investigations, and systematic reviews published between 2009 and 2025. Sample sizes ranged from 20 to 414 participants. All studies involved adult patients (≥18 years) with TRD, defined as inadequate response to at least one prior antidepressant trial. The majority of studies compared accelerated iTBS protocols - defined as delivering ≥2 sessions per day over ≤10 days - with standard daily rTMS administered over 4-6 weeks. Most protocols targeted the left DLPFC, using the FDA-approved iTBS parameters (600 pulses delivered over three minutes per session). Outcome Reporting All 25 studies contributed to the qualitative synthesis; however, not all were suitable for tabular presentation. Narrative and mechanistic reviews, registry-based analyses, cognitive testing studies, and small feasibility trials are discussed narratively in the text but excluded from Tables 3, 4. These studies added important insights regarding neurobiological rationale, cognitive safety, feasibility, and real-world implementation. By contrast, only randomized controlled trials and observational studies reporting extractable clinical efficacy and safety outcomes are summarized in Tables 3, 4. These tables consolidate key findings on response, remission, dropout rates, and adverse events across the most robust evidence base. The heterogeneity of study designs, stimulation protocols, and follow-up durations limited the feasibility of meta-analysis; therefore, a qualitative synthesis was conducted. Discussion Interpretation of Findings The findings of this review indicate that accelerated intermittent theta burst stimulation (aiTBS) represents a practical and time-efficient alternative to conventional rTMS for the treatment of individuals with TRD. Across several randomized trials and real-world clinical reports, aiTBS has shown antidepressant effects that are broadly comparable to standard rTMS, with some evidence pointing toward faster symptom improvement and better treatment adherence [6-8,27]. The pivotal THREE-D trial demonstrated that daily iTBS produced clinical outcomes equivalent to high-frequency rTMS despite the considerable reduction in session duration [6]. More intensive, accelerated schedules, such as the multi-session SAINT protocol described by Cole et al. [8], have achieved rapid and robust symptom reductions over a compressed five-day course. Although Cash et al. [7] focused primarily on neural predictors of response rather than remission, their findings support the clinical relevance of iTBS by linking pretreatment subgenual connectivity patterns with subsequent therapeutic benefit. Collectively, these results suggest that compressing treatment into an accelerated schedule does not diminish the antidepressant effect and may offer meaningful logistical advantages for patients who struggle to complete lengthy 4-6-week treatment courses. Neurobiological Mechanisms TBS is grounded in mechanisms of activity-dependent neuroplasticity. The iTBS protocol replicates endogenous theta rhythms observed in the hippocampus, pairing 5-Hz cycles with 50-Hz bursts to induce long-term potentiation-like effects in cortical networks [5,17]. When applied to the DLPFC, iTBS modulates frontolimbic and corticostriatal-thalamic circuits involved in affective regulation, which may explain its rapid clinical onset compared with traditional rTMS paradigms [11,14,18]. Neuroplasticity-related biomarkers offer additional insight into these mechanisms. Brain-derived neurotrophic factor (BDNF), a mediator of synaptic strengthening, has been shown to increase following successful neuromodulation treatments. Early evidence suggests that iTBS may enhance BDNF expression and augment functional connectivity within emotion-regulation networks [17,19]. Price et al. [14] further demonstrated that orbitofrontal cortex activity during stimulation was associated with clinical outcomes, reinforcing the role of network-level modulation in predicting response. Accelerated delivery schedules may amplify these neuroplastic effects by providing more cumulative stimulation within a shorter timeframe, thereby reinforcing synaptic potentiation and potentially reducing the lag between treatment initiation and clinical improvement [6,7]. This accelerated therapeutic trajectory is particularly relevant for individuals with severe TRD, where early symptom relief may substantially impact functioning and safety (Figure 3) [1,3]. Four neuromodulation interventions commonly investigated in the management of treatment-resistant depression (TRD): deep brain stimulation (DBS), vagus nerve stimulation (VNS), repetitive transcranial magnetic stimulation (rTMS), and intermittent theta burst stimulation (iTBS) Each column outlines the type of stimulation, primary neuroanatomical targets, stimulation frequency or protocol, and degree of invasiveness. DBS is invasive, targeting deep brain structures (midbrain, thalamus, pallidum). VNS is moderately invasive, acting on the vagus nerve via implanted devices. rTMS and iTBS are non-invasive brain stimulation modalities that target the dorsolateral prefrontal cortex (DLPFC). Unlike standard rTMS sessions lasting ~37.5 minutes, iTBS delivers 600 pulses in approximately three minutes and can be administered in accelerated schedules with multiple sessions per day. Image credits: Ayushi Saxena Created with BioRender.com [9] Cognitive Outcomes Concerns regarding potential cognitive adverse effects of neuromodulation were not supported by the studies reviewed. Across the available evidence, iTBS and related protocols were consistently associated with neutral or modestly favorable cognitive outcomes, with no reports of treatment-emergent cognitive decline [11,12,14]. McClintock and colleagues [11] synthesized results from multiple neuromodulation trials and concluded that TMS-based interventions generally preserve cognitive functioning, while their subsequent work [12] further highlighted that accelerated stimulation does not impair attention, memory, or processing speed. Price et al. [14] also noted improvements in functional connectivity within regions implicated in cognitive control, suggesting that neuromodulatory effects may extend beyond mood regulation. These findings carry important clinical implications, particularly for individuals with TRD who frequently present with baseline cognitive deficits due to chronic illness, polypharmacy, or comorbid conditions. Unlike many pharmacologic augmentation strategies that introduce anticholinergic or sedating side effects, iTBS appears to provide antidepressant benefits without imposing additional cognitive burden [13,21]. Safety and Tolerability Across trials, accelerated iTBS protocols demonstrated strong tolerability profiles, with dropout rates generally below 10% and adverse events limited to mild, transient symptoms such as scalp discomfort or headache [6-8,11,20]. Even in high-intensity paradigms, such as the multi-session daily schedule used by Cash et al. [7], no serious adverse events were observed. The deep TMS protocol evaluated by Blumberger et al. [20] similarly reported good safety outcomes alongside improvements in mood and cerebral perfusion. These results contrast sharply with the adherence challenges commonly observed in medication-based TRD treatments, in which side effects frequently lead to early discontinuation. Furthermore, iTBS does not require anesthesia or sedation - elements that limit accessibility to electroconvulsive therapy - making it a practical option for outpatient settings [3,18]. Population-Specific Considerations Accelerated neuromodulation protocols offer particular value for individuals who face barriers to completing lengthy treatment courses, including patients living in rural or underserved areas and those constrained by work, caregiving responsibilities, or mobility limitations [4,27]. Condensing several weeks of treatment into a 5- to 7-day schedule can substantially expand access and feasibility for these groups. However, population-level evidence remains incomplete. Several included studies excluded older adults, patients with significant medical comorbidities, or individuals receiving multiple concurrent medications, limiting the generalizability of current findings [26]. Sex-specific response patterns were not reported in any trial. Kalin’s work [15,16,24,25] underscores the need for future investigations to incorporate more diverse clinical samples to better reflect real-world TRD populations. Emerging evidence from cognitive and neuropsychological research also suggests that individuals with baseline executive dysfunction or psychomotor slowing features commonly observed in more severe or chronic TRD may derive additional benefit from neuromodulatory interventions. Recent meta-analytic work has shown improvements in executive functioning and processing speed following non-invasive brain stimulation [21], while systematic evaluations of TBS-specific protocols in TRD populations report similarly favorable neurocognitive profiles [23]. When neuromodulation is paired with psychological interventions or cognitive remediation, synergistic effects on both mood and cognitive outcomes have also been noted [22]. Strengths and Limitations of the Literature The current evidence base includes several large, methodologically rigorous randomized controlled trials with standardized outcome measures such as the HAM-D and MADRS, alongside real-world registry studies that enhance generalizability [6-8,11,18]. Mechanistic contributions from neuroimaging and biomarker research help situate iTBS within a broader neurobiological framework and support its hypothesized mechanisms of action [14,17]. Nonetheless, important limitations persist. A substantial proportion of trials were modest in size [7,11,19], increasing susceptibility to type I and type II errors. Several studies used open-label or non-comparative designs, which may introduce performance or detection bias. Most follow-up periods were short, often four weeks or less, which limits conclusions about the durability of antidepressant effects and the long-term risk of relapse. Protocol heterogeneity also complicates interpretation. Differences in pulse dose, session frequency, coil positioning, and targeting approaches introduce variability that reduces comparability across studies [6,8,11]. Although low-quality studies were excluded from this review, several included publications were mechanistic or editorial in nature [16,18,24,25], contributing conceptual value but limited empirical effect-size data. Language and publication restrictions may further constrain generalizability, as only peer-reviewed, English-language studies were included. This approach enhances internal validity but may exclude relevant global perspectives. Furthermore, the operational definition of TRD was not fully consistent across included studies, with variation in the number and stringency of prior failed antidepressant trials required for inclusion; this heterogeneity may limit the direct comparability of response and remission rates reported across studies [2]. Taken together, the available evidence supports accelerated iTBS as a time-efficient, well-tolerated, and mechanistically grounded intervention for TRD. However, additional multicenter randomized trials with larger samples, longer follow-up durations, standardized stimulation parameters, and biomarker-informed designs are needed to clarify optimal protocols, durability of benefit, and population-specific response patterns. Recommendations Based on the evidence synthesized in this review, we recommend that (1) future trials adopt standardized, consensus-based definitions of TRD to improve comparability across studies; (2) larger multicenter randomized controlled trials be conducted with longer follow-up periods (beyond four weeks) to establish the durability of antidepressant response to accelerated iTBS; (3) trial protocols be prospectively registered to improve methodological transparency; (4) future studies include more diverse populations, including older adults and patients with medical comorbidities, to improve generalizability; and (5) stimulation parameters (pulse dose, sessions per day, total treatment duration) be systematically compared to identify optimal accelerated protocols. Conclusions Accelerated iTBS has gained strong support as a practical, well-tolerated, and clinically effective alternative to conventional daily rTMS for TRD. The available evidence demonstrates that accelerated iTBS can achieve meaningful antidepressant response and remission rates while reducing treatment time from several weeks to just a few days, greatly improving convenience and feasibility for both patients and clinical services. Across studies, cognitive functioning remained stable or showed modest improvement, and adverse effects were generally mild, with low dropout rates further underscoring its favorable tolerability profile. These advantages make accelerated iTBS particularly well suited for settings where timely access to care is critical or where prolonged treatment schedules pose barriers to engagement. Nevertheless, the current literature is limited by short follow-up periods and underrepresentation of older adults, medically complex patients, and other key clinical subgroups. Larger, longer-term trials with standardized stimulation parameters and broader participant diversity are needed to clarify the durability of benefit and inform best-practice clinical implementation. Taken together, the existing evidence supports accelerated iTBS as a promising advancement in neuromodulation and a valuable option for individuals who have not benefited from traditional antidepressant therapies.